
DarioHealth (DRIO) Stock Forecast & Price Target
DarioHealth (DRIO) Analyst Ratings
Bulls say
DarioHealth is well-positioned to capitalize on the growing digital therapeutics market as it continues to expand its vertical integration strategy and deliver personalized evidence-based interventions. With strong channel partner traction, improving gross margins, and a target break-even cash flow by 1Q27, the company's focus on enterprise adoption and growth will likely lead to share gains, upward earnings revision, and multiple expansion. However, DarioHealth faces potential risks associated with the HCIT industry, such as government program cuts and price competition.
Bears say
DarioHealth is currently performing well, with a strong B2C revenue of $2.9M in Q1 and a growing pipeline of $127M. However, a challenging digital health demand environment and potential limited investment by DRIO may hinder revenue growth, and their recent dilutive capital raise suggests potential struggles in the near to medium term. Their 2027 revenue and EBITDA estimates have been adjusted slightly, and there is potential for upside if they can cross-sell to legacy Twill customers and control OpEx better.
This aggregate rating is based on analysts' research of DarioHealth and is not a guaranteed prediction by Public.com or investment advice.
DarioHealth (DRIO) Analyst Forecast & Price Prediction
Start investing in DarioHealth (DRIO)
Order type
Buy in
Order amount
Est. shares
0 shares